Payment overview · 2025
General Payments
$191.89
3 reported records · 2 companies
Healthcare provider profile · identity verified
Tabitha Ann Johnson, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · FRANKLIN, IN · NPI 1336299221
Verified facts
What the public records show
CMS Open Payments records show Tabitha Ann Johnson, NP received $191.89 in general payments during 2025 across 3 reported records.
REVANCE THERAPEUTICS, INC. accounted for 90.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $173.28 | 90.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.61 | 9.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $191.89 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $173.28 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 424 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 70 |
| Lisinopril | Lisinopril | 201 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 159 | 35 |
| Omeprazole | Omeprazole | 152 | 38 |
| Glimepiride | Glimepiride | 147 | 43 |
| Losartan Potassium | Losartan Potassium | 131 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 37 |
| Metformin Hcl | Metformin Hcl | 109 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 108 | 30 |
| Gabapentin | Gabapentin | 104 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 100 | 29 |
| Montelukast Sodium | Montelukast Sodium | 91 | 22 |
| Alendronate Sodium | Alendronate Sodium | 85 | 18 |
| Tramadol Hcl | Tramadol Hcl | 83 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 80 | 23 |
| Januvia | Sitagliptin Phosphate | 80 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 22 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 76 | 54 |
| Alprazolam | Alprazolam | 75 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 22 |
| Potassium Chloride | Potassium Chloride | 72 | 20 |
| Sertraline Hcl | Sertraline Hcl | 70 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 22 |
| Mounjaro | Tirzepatide | 68 | 13 |
| Trazodone Hcl | Trazodone Hcl | 68 | 22 |
| Allopurinol | Allopurinol | 67 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 66 | 17 |
| Metformin Hcl Er | Metformin Hcl | 65 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 62 | 16 |
| Ozempic | Semaglutide | 61 | 12 |
| Naproxen | Naproxen | 59 | suppressed |
| Mirtazapine | Mirtazapine | 58 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 16 |
| Simvastatin | Simvastatin | 56 | 17 |
| Buspirone Hcl | Buspirone Hcl | 55 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 15 |
| Famotidine | Famotidine | 49 | 16 |
| Ezetimibe | Ezetimibe | 48 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 15 |
| Jardiance | Empagliflozin | 48 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 11 |
| Furosemide | Furosemide | 42 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 35 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 19 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | 11 |
| Baclofen | Baclofen | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 27 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 12 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Eliquis | Apixaban | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 18 |
| Pregabalin | Pregabalin | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 13 |
| Nystatin | Nystatin | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Desonide | Desonide | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $191.89 · 3 records | REVANCE THERAPEUTICS, INC. | DAXXIFY, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error